Tag: next generation cancer diagnostics market size

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Next Generation Cancer Diagnostics Market Expected To Reach $26.44 Billion By 2030 At 12.9% CAGR

The market for next-generation cancer diagnostics has experienced substantial expansion lately. Projections indicate a rise from $14.4 billion in 2025 to $16.29 billion in 2026, reflecting a compound annual growth rate of 13.2%. Key factors driving this historical expansion include an increase in cancer occurrences, significant progress in genomic sequencing techniques, a greater acceptance of biomarker-driven diagnostic methods within clinical settings, increased investment in oncology research, and a heightened need for personalized diagnostic approaches.

The burgeoning field of next-generation cancer diagnostics is poised for substantial expansion, with projections indicating a market valuation of $26.44 billion by the year 2030, a trajectory fueled by a robust compound annual growth rate of 12.9%. This anticipated surge is largely propelled by the increasing embrace of tailored medical treatments, augmented financial commitments to sophisticated cancer detection initiatives, a greater reliance on less invasive diagnostic techniques, the broadening scope of companion diagnostic development, and the escalating incorporation of artificial intelligence for clinical decision support. Key developments shaping this period include a heightened utilization of liquid biopsy technology, a more widespread application of multi-omics diagnostic platforms, the increasing integration of AI-powered cancer analysis tools, the expansion of individualized oncology diagnostics, and a more concentrated effort on identifying cancer in its nascent stages.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30336&type=smp

Next Generation Cancer Diagnostics Market Expansion Supported By Key Demand Factors

The expansion of the market for next-generation cancer diagnostics is anticipated to be significantly fueled by a growing need for customized medical treatments. These tailored medical interventions, known as personalized medicines, are designed to align with an individual’s unique genetic composition, daily habits, and surroundings, thereby ensuring the most beneficial therapeutic approach for that particular patient. Such a heightened demand for personalized medicine stems from the escalating occurrence of long-term and uncommon ailments, which consequently require specialized, patient-focused treatments for superior therapeutic results. Next-generation cancer diagnostics are instrumental in facilitating personalized medicine by offering detailed molecular information that informs customized treatment plans, specifically adapted to a patient’s distinct genetic and tumor characteristics. As an illustration, FDA approvals for personalized therapies targeting rare diseases saw a notable increase in 2023, reaching 16 compared to just six in 2022, as reported by the Personalized Medicine Coalition in February 2024, underscoring the market’s upward trajectory driven by personalized medicine advancements.

Next Generation Cancer Diagnostics Market Segment Performance And Strategic Opportunities

The next generation cancer diagnostics market covered in this report is segmented –

1) By Technology: Next-Generation Sequencing (NGS), Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays, Protein Microarrays, Deoxyribonucleic Acid Microarrays, Other Multi-Omics Platforms

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer

3) By Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis

4) By Application: Biomarker Development, Circulating Tumor Cell (CTC) Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis

5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Pharmaceutical And Biotechnology Companies, Home Care Settings

Subsegments:

1) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing

2) By Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction: Microfluidic Chip Assays, Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips, Point-of-Care Lab-On-A-Chip Devices, High-Throughput Lab-On-A-Chip Systems

3) By Circulating Tumor Deoxyribonucleic Acid Assays: Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays, Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels, Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays, Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays

4) By Protein Microarrays: Analytical Protein Microarrays, Functional Protein Microarrays, Reverse Phase Protein Microarrays, Antibody-Based Protein Microarrays

5) By Deoxyribonucleic Acid Microarrays: Gene Expression Deoxyribonucleic Acid Microarrays, Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays, Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays, Methylation Deoxyribonucleic Acid Microarrays

6) By Other Multi-Omics Platforms: Metabolomics Platforms, Epigenomics Platforms, Transcriptomics Platforms, Integrated Multi-Omics Systems

Next Generation Cancer Diagnostics Market Growth Trends Influencing Competitive Dynamics

Leading players in the evolving landscape of next-generation cancer diagnostics are prioritizing the creation of cutting-edge technologies, specifically AI-powered systems capable of analyzing diverse data types, to refine early identification, tailor treatments, and improve therapeutic recommendations. These sophisticated platforms leverage artificial intelligence to consolidate and interpret various biological datasets, encompassing genetic, protein, imaging, and patient health information, thereby achieving greater precision and customization in cancer detection and diagnosis. As an illustration, in April 2025, OneCell Diagnostics Pvt Ltd., a firm specializing in personalized oncology based in India, introduced OncoIncytes, a diagnostic instrument designed for multi-faceted cancer assessment within the realm of precision oncology. This platform integrates a spectrum of data, including DNA shed by tumors, individual tumor cells circulating in the bloodstream, RNA profiles, and comprehensive protein data for 150 proteins at the single-cell level. Driven by a 1080-gene array augmented by AI and machine learning algorithms, OncoIncytes generates highly sensitive and specific analytical results that are anticipated to yield better outcomes in clinical trials, with a particular emphasis on early-stage investigations and the progression of antibody-drug conjugate therapies. The system facilitates bespoke cancer identification, treatment progress tracking, and pharmaceutical advancement through diagnostic methods that are non-invasive, continuously updated, and adaptable in scale, all readily available through OneCell’s exclusive iDiscover application and processed in a CLIA-certified facility.

Next Generation Cancer Diagnostics Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.

Access The Complete Next Generation Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/global-next-generation-cancer-diagnostics-market-report

Next Generation Cancer Diagnostics Market Global Footprint: Which Region Holds Market Leadership?

North Americawas the largest region in the next generation cancer diagnostics market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the next generation cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Value Of The Next Generation Cancer Diagnostics Market Projected To Expand During 2026–2030?

The next generation cancer diagnostics market size has experienced swift expansion in recent years. This market is projected to grow from $14.4 billion in 2025 to $16.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.2%. Historically, this growth can be attributed to factors such as increasing cancer incidence rates, advancements in genomic sequencing technologies, a rise in the clinical adoption of biomarker-based diagnostics, an expansion of oncology research funding, and a growing demand for precision diagnostics.

The next generation cancer diagnostics market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach a valuation of $26.44 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.9%. This expansion during the projected timeframe is largely due to the wider embrace of personalized medicine strategies, heightened capital expenditure in advanced cancer screening initiatives, an escalating reliance on minimally invasive diagnostic techniques, the broader development of companion diagnostics, and the greater incorporation of AI-powered clinical decision support systems. Key developments anticipated for this period encompass the increased uptake of liquid biopsy technologies, a surging application of multi-omics diagnostic platforms, the deepening integration of AI-based cancer analytics, the spread of personalized oncology diagnostics, and a heightened emphasis on identifying cancer at earlier stages.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30336&type=smp

Which Significant Factors Are Encouraging Growth In The Next Generation Cancer Diagnostics Market?

The escalating need for personalized medicines is anticipated to propel the expansion of the next generation cancer diagnostics market moving forward. Personalized medicines are medical treatments specifically tailored to an individual’s genetic makeup, lifestyle, and environment, ensuring the most effective therapy for that particular patient. This heightened demand for personalized medicines arises from the increasing prevalence of chronic and rare diseases, which necessitate targeted, patient-specific therapies to achieve more favorable treatment outcomes. Next generation cancer diagnostics enable personalized medicine by offering precise molecular insights that guide customized treatment strategies based on an individual patient’s unique genetic and tumor profile. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, marking a substantial increase from the six approvals recorded in 2022. Consequently, the growing demand for personalized medicines is driving the growth of the next generation cancer diagnostics market.

How Are Different Segment Groups Identified Within The Next Generation Cancer Diagnostics Market?

The next generation cancer diagnostics market covered in this report is segmented –

1) By Technology: Next-Generation Sequencing (NGS), Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays, Protein Microarrays, Deoxyribonucleic Acid Microarrays, Other Multi-Omics Platforms

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer

3) By Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis

4) By Application: Biomarker Development, Circulating Tumor Cell (CTC) Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis

5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Pharmaceutical And Biotechnology Companies, Home Care Settings

Subsegments:

1) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing

2) By Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction: Microfluidic Chip Assays, Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips, Point-of-Care Lab-On-A-Chip Devices, High-Throughput Lab-On-A-Chip Systems

3) By Circulating Tumor Deoxyribonucleic Acid Assays: Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays, Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels, Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays, Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays

4) By Protein Microarrays: Analytical Protein Microarrays, Functional Protein Microarrays, Reverse Phase Protein Microarrays, Antibody-Based Protein Microarrays

5) By Deoxyribonucleic Acid Microarrays: Gene Expression Deoxyribonucleic Acid Microarrays, Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays, Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays, Methylation Deoxyribonucleic Acid Microarrays

6) By Other Multi-Omics Platforms: Metabolomics Platforms, Epigenomics Platforms, Transcriptomics Platforms, Integrated Multi-Omics Systems

What Trends Are Driving Changes In The Next Generation Cancer Diagnostics Market?

Leading companies within the neurotrophic keratitis market are concentrating on creating sophisticated gene-therapy options, including redosable eye-drop treatments. These innovations aim to enhance corneal healing, ensure consistent nerve growth factor (NGF) expression, and alleviate the burden of treatment for patients. Redosable eye-drop gene therapy involves a medical strategy where genes that encode NGF are directly delivered to the cornea, allowing for extended NGF production and supporting nerve regeneration over time. A notable example is Krystal Biotech, a US-based biotechnology company, which announced in July 2025 that the initial patient had received a dose in its Phase 1/2 EMERALD 1 study. This trial is a randomized, double-masked, placebo-controlled study enrolling up to 27 adults suffering from stage 2 or 3 neurotrophic keratitis. KB801, intended for twice-weekly administration over eight weeks, is designed to safely encourage corneal healing while substantially lessening the treatment frequency compared to current six-times-a-day recombinant NGF eye drops.

Who Are The Key Market Participants In The Next Generation Cancer Diagnostics Market?

Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.

Access The Complete Next Generation Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/global-next-generation-cancer-diagnostics-market-report

Which Region Leads The Next Generation Cancer Diagnostics Market By Size?

North America was the largest region in the next generation cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Next Generation Cancer Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=30336&type=smp

Browse Through More Reports Similar to the Global Next Generation Cancer Diagnostics Market 2026, By The Business Research Company

Peripheral Neuropathy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Chronic Pain Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Neuralgia Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Next Generation Cancer Diagnostics Market Expected To Scale Between 2026 And 2030?

The next generation cancer diagnostics market size has experienced rapid expansion in recent years. This market is anticipated to expand from $14.4 billion in 2025 to $16.29 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.2%. Historically, this upward trend can be ascribed to factors including increasing cancer incidence rates, progress in genomic sequencing technologies, the growing clinical acceptance of biomarker-based diagnostics, an increase in oncology research funding, and a rising need for precision diagnostics.

The next generation cancer diagnostics market size is anticipated to undergo significant expansion over the upcoming years. It is forecast to achieve a valuation of $26.44 billion by 2030, advancing at a compound annual growth rate (CAGR) of 12.9%. The projected increase in this period can be ascribed to a heightened embrace of personalized medicine approaches, rising investments in advanced cancer screening programs, a growing reliance on minimally invasive diagnostic methods, the expansion of companion diagnostics development, and the increasing incorporation of AI-driven clinical decision support. Key trends identified for the forecast period include a greater adoption of liquid biopsy technologies, an increasing utilization of multi-omics diagnostic platforms, the expanding integration of AI-based cancer analytics, the broadening of personalized oncology diagnostics, and an amplified focus on early-stage cancer detection.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30336&type=smp

Which Factors Are Influencing The Growth Of The Next Generation Cancer Diagnostics Market?

The rising need for personalized medicines is anticipated to boost expansion within the next generation cancer diagnostics market in the future. These medicines are defined as medical treatments specifically designed for an individual’s unique genetic profile, way of life, and surroundings, aiming to deliver the most effective care for that particular patient. This growing demand stems from the increasing incidence of chronic and rare illnesses, which require specialized, patient-focused therapies to achieve better treatment results. Next generation cancer diagnostics facilitate personalized medicine by offering accurate molecular data, which helps in formulating customized treatment plans according to a patient’s distinct genetic and tumor characteristics. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit body, reported that the FDA granted approval to 16 new personalized therapies for rare disease patients in 2023, representing a significant increase from the six approvals seen in 2022. Consequently, the heightened need for personalized medicines is a key factor driving the expansion of the next generation cancer diagnostics market.

Which Segment Types Are Examined In The Next Generation Cancer Diagnostics Market Segment Study?

The next generation cancer diagnostics market covered in this report is segmented –

1) By Technology: Next-Generation Sequencing (NGS), Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays, Protein Microarrays, Deoxyribonucleic Acid Microarrays, Other Multi-Omics Platforms

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer

3) By Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis

4) By Application: Biomarker Development, Circulating Tumor Cell (CTC) Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis

5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Pharmaceutical And Biotechnology Companies, Home Care Settings

Subsegments:

1) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing

2) By Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction: Microfluidic Chip Assays, Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips, Point-of-Care Lab-On-A-Chip Devices, High-Throughput Lab-On-A-Chip Systems

3) By Circulating Tumor Deoxyribonucleic Acid Assays: Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays, Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels, Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays, Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays

4) By Protein Microarrays: Analytical Protein Microarrays, Functional Protein Microarrays, Reverse Phase Protein Microarrays, Antibody-Based Protein Microarrays

5) By Deoxyribonucleic Acid Microarrays: Gene Expression Deoxyribonucleic Acid Microarrays, Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays, Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays, Methylation Deoxyribonucleic Acid Microarrays

6) By Other Multi-Omics Platforms: Metabolomics Platforms, Epigenomics Platforms, Transcriptomics Platforms, Integrated Multi-Omics Systems

Which Trends Are Influencing Demand In The Next Generation Cancer Diagnostics Market?

Companies operating in the next generation cancer diagnostics market are concentrating on developing innovative solutions like artificial intelligence-driven multi-modal diagnostic platforms to improve early detection, personalized treatment, and clinical decision-making. These artificial intelligence-driven multi-modal diagnostic platforms are advanced systems that leverage artificial intelligence to integrate and analyze various biological data types, including genomic, proteomic, imaging, and clinical information, thereby providing more accurate and personalized cancer detection and diagnosis. For instance, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, launched OncoIncytes, a multi-modal cancer diagnostic platform specifically designed for precision oncology. This platform combines different data types, such as circulating tumor DNA, single-cell circulating tumor cells, RNA information, and detailed protein profiles of 150 proteins at the single-cell level. Utilizing a 1080-gene panel powered by AI and machine learning, OncoIncytes delivers highly sensitive and specific insights to enhance clinical trial outcomes, particularly in early-stage research and antibody-drug conjugate development. The platform enables personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, all accessible via OneCell’s proprietary iDiscover application from a CLIA-certified laboratory.

Which Players Are Part Of The Competitive Landscape Of The Next Generation Cancer Diagnostics Market?

Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.

Get The Full Next Generation Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/global-next-generation-cancer-diagnostics-market-report

Which Region Represents The Largest Share Of The Next Generation Cancer Diagnostics Market?

North America was the largest region in the next generation cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Next Generation Cancer Diagnostics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/global-next-generation-cancer-diagnostics-market-report

Browse Through More Reports Similar to the Global Next Generation Cancer Diagnostics Market 2026, By The Business Research Company

Peripheral Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Chronic Pain Market Report

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Neuralgia Treatment Market Report

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Next Generation Cancer Diagnostics Market Across 2026–2030?

The next generation cancer diagnostics market has experienced significant expansion in recent years. This market is projected to expand from $14.4 billion in 2025 to $16.29 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.2%. Historically, this growth has been driven by factors such as the rising incidence of cancer, breakthroughs in genomic sequencing technologies, wider clinical acceptance of diagnostics based on biomarkers, increased funding for oncology research, and a growing need for precise diagnostic methods.

The market for next generation cancer diagnostics is projected to experience substantial expansion in the coming years. It is anticipated to reach $26.44 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.9%. This expansion over the forecast period stems from factors such as the greater acceptance of personalized medicine approaches, increased funding for sophisticated cancer screening initiatives, the wider application of minimally invasive diagnostic techniques, the growth in companion diagnostics development, and the deeper incorporation of AI-powered clinical decision support. Key developments foreseen during this period encompass the accelerated embrace of liquid biopsy technologies, the expanding utilization of multi-omics diagnostic platforms, the deepening integration of AI-based cancer analytics, the widening scope of personalized oncology diagnostics, and a heightened emphasis on identifying cancer at its initial stages.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30336&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Next Generation Cancer Diagnostics Market?

A rising demand for personalized medicines is anticipated to boost the expansion of the next generation cancer diagnostics market in the future. These medicines represent medical interventions customized to a person’s genetic composition, way of life, and surroundings, aiming to deliver the most effective treatment for their particular case. This growing need for personalized medicines stems from the increasing occurrence of chronic and rare diseases, which require precise, patient-focused therapies to achieve better treatment results. Next generation cancer diagnostics facilitate personalized medicine by offering accurate molecular data that informs customized treatment approaches, considering an individual patient’s distinct genetic and tumor characteristics. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA sanctioned 16 novel personalized therapies for individuals suffering from rare diseases, indicating a significant increase from the six approvals noted in 2022. Consequently, the expanding requirement for personalized medicines is fueling the development of the next generation cancer diagnostics market.

What Segmentation Levels Are Considered In The Next Generation Cancer Diagnostics Market?

The next generation cancer diagnostics market covered in this report is segmented –

1) By Technology: Next-Generation Sequencing (NGS), Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays, Protein Microarrays, Deoxyribonucleic Acid Microarrays, Other Multi-Omics Platforms

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer

3) By Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis

4) By Application: Biomarker Development, Circulating Tumor Cell (CTC) Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis

5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Pharmaceutical And Biotechnology Companies, Home Care Settings

Subsegments:

1) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing

2) By Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction: Microfluidic Chip Assays, Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips, Point-of-Care Lab-On-A-Chip Devices, High-Throughput Lab-On-A-Chip Systems

3) By Circulating Tumor Deoxyribonucleic Acid Assays: Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays, Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels, Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays, Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays

4) By Protein Microarrays: Analytical Protein Microarrays, Functional Protein Microarrays, Reverse Phase Protein Microarrays, Antibody-Based Protein Microarrays

5) By Deoxyribonucleic Acid Microarrays: Gene Expression Deoxyribonucleic Acid Microarrays, Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays, Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays, Methylation Deoxyribonucleic Acid Microarrays

6) By Other Multi-Omics Platforms: Metabolomics Platforms, Epigenomics Platforms, Transcriptomics Platforms, Integrated Multi-Omics Systems

What Industry Trends Are Redefining The Next Generation Cancer Diagnostics Market?

Leading companies in the next generation cancer diagnostics market are concentrating on developing innovative solutions, including artificial intelligence-driven multi-modal diagnostic platforms, to improve early detection, personalized treatment, and clinical decision-making. These AI-driven multi-modal diagnostic platforms are advanced systems that utilize artificial intelligence to integrate and analyze various types of biological data, such as genomic, proteomic, imaging, and clinical information, for more accurate and personalized cancer detection and diagnosis. For instance, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, launched OncoIncytes, a multi-modal cancer diagnostic platform specifically designed for precision oncology. The platform combines diverse data types, including circulating tumor DNA, single-cell circulating tumor cells, RNA information, and detailed protein profiles of 150 proteins at the single-cell level. By employing a 1080-gene panel powered by AI and machine learning, OncoIncytes delivers highly sensitive and specific insights to enhance clinical trial outcomes, particularly in early-stage research and antibody-drug conjugate development. The platform facilitates personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, all accessible via OneCell’s proprietary iDiscover application from a CLIA-certified laboratory.

Which Leading Firms Are Contributing To The Growth Of The Next Generation Cancer Diagnostics Market?

Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.

Read the full next generation cancer diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/global-next-generation-cancer-diagnostics-market-report

Which Regions Are Projected To Dominate The Next Generation Cancer Diagnostics Market In The Coming Years?

North America was the largest region in the next generation cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Next Generation Cancer Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30336&type=smp

Browse Through More Reports Similar to the Global Next Generation Cancer Diagnostics Market 2026, By The Business Research Company

Peripheral Neuropathy Global Market Report

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Chronic Pain Global Market Report

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Neuralgia Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the next generation cancer diagnostics market from 2026–2035 with trusted insights from The Business Research Company

How is the Next Generation Cancer Diagnostics Market size predicted to change over the forecast window of 2026–2035?

The next generation cancer diagnostics market size has seen rapid expansion in recent years. It is forecast to grow from $14.4 billion in 2025 to $16.29 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.2%. The historical increase can be attributed to several factors including rising cancer incidence rates, advancements in genomic sequencing technologies, increasing clinical adoption of biomarker-based diagnostics, expanded funding for oncology research, and a growing demand for precision diagnostics.

The next generation cancer diagnostics market size is projected to experience substantial growth in the upcoming years. It is anticipated to expand to $26.44 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.9%. This expansion during the forecast period is driven by increasing adoption of personalized medicine approaches, rising investments in advanced cancer screening programs, growing use of minimally invasive diagnostic methods, expansion of companion diagnostics development, and increasing integration of AI-driven clinical decision support. Prominent trends for the forecast period encompass increasing adoption of liquid biopsy technologies, rising use of multi-omics diagnostic platforms, growing integration of AI-based cancer analytics, expansion of personalized oncology diagnostics, and an enhanced focus on early-stage cancer detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30336&type=smp

Which Drivers Are Contributing To The Expansion Of The Next Generation Cancer Diagnostics Market?

The expanding requirement for personalized medicines is projected to propel the growth of the next generation cancer diagnostics market going forward. Personalized medicines refer to medical treatments specifically designed for an individual’s genetic makeup, lifestyle, and environment to ensure the most effective therapy for that particular patient. This heightened demand stems from the increasing occurrence of chronic and rare diseases, which necessitate focused, patient-specific therapies for more effective treatment outcomes. Next generation cancer diagnostics facilitate personalized medicine by providing accurate molecular insights that guide customized treatment strategies based on an individual patient’s unique genetic and tumor profile. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, marking a notable increase from the six approvals recorded in 2022. Therefore, the rising demand for personalized medicines is a key factor driving the growth of the next generation cancer diagnostics market.

What Segment Classifications Make Up The Next Generation Cancer Diagnostics Market?

The next generation cancer diagnostics market covered in this report is segmented –

1) By Technology: Next-Generation Sequencing (NGS), Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays, Protein Microarrays, Deoxyribonucleic Acid Microarrays, Other Multi-Omics Platforms

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer

3) By Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis

4) By Application: Biomarker Development, Circulating Tumor Cell (CTC) Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis

5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Pharmaceutical And Biotechnology Companies, Home Care Settings

Subsegments:

1) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing

2) By Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction: Microfluidic Chip Assays, Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips, Point-of-Care Lab-On-A-Chip Devices, High-Throughput Lab-On-A-Chip Systems

3) By Circulating Tumor Deoxyribonucleic Acid Assays: Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays, Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels, Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays, Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays

4) By Protein Microarrays: Analytical Protein Microarrays, Functional Protein Microarrays, Reverse Phase Protein Microarrays, Antibody-Based Protein Microarrays

5) By Deoxyribonucleic Acid Microarrays: Gene Expression Deoxyribonucleic Acid Microarrays, Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays, Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays, Methylation Deoxyribonucleic Acid Microarrays

6) By Other Multi-Omics Platforms: Metabolomics Platforms, Epigenomics Platforms, Transcriptomics Platforms, Integrated Multi-Omics Systems

Which Market Trends Are Opening Growth Opportunities In The Next Generation Cancer Diagnostics Market?

Leading companies in the next generation cancer diagnostics market are concentrating on developing innovative solutions, such as artificial intelligence-driven multi-modal diagnostic platforms, to improve early detection, personalized treatment, and clinical decision-making. These artificial intelligence-driven multi-modal diagnostic platforms are advanced systems that utilize artificial intelligence to integrate and analyze various types of biological data, including genomic, proteomic, imaging, and clinical information, to deliver more accurate and personalized cancer detection and diagnosis. For instance, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, unveiled OncoIncytes, a multi-modal cancer diagnostic platform tailored for precision oncology. This platform integrates diverse data types, such as circulating tumor DNA, single-cell circulating tumor cells, RNA information, and detailed protein profiles of 150 proteins at the single-cell level. Leveraging a 1080-gene panel powered by AI and machine learning, OncoIncytes provides highly sensitive and specific insights to enhance clinical trial outcomes, particularly in early-stage research and antibody-drug conjugate development. The platform allows for personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, all accessible via OneCell’s proprietary iDiscover application from a CLIA-certified laboratory.

Which Key Market Players Are Investing In Expansion And Innovation Within The Next Generation Cancer Diagnostics Market?

Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/global-next-generation-cancer-diagnostics-market-report

Which Regions Are Projected To Dominate The Next Generation Cancer Diagnostics Market In The Coming Years?

North America was the largest region in the next generation cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Next Generation Cancer Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30336&type=smp

Browse Through More Reports Similar to the Global Next Generation Cancer Diagnostics Market 2026, By The Business Research Company

Oncology Companion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Next Generation Gynecological Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-gynecological-cancer-diagnostics-global-market-report

Breast Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model